Synthetic Cannabinoid-Induced Immunosuppression Augments Cerebellar Dysfunction in Tetanus-Toxin Treated Mice |
Yun, Jaesuk
(National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Gu, Sun Mi (National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Lee, Tac-hyung (National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Song, Yun Jeong (National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Seong, Seonhwa (National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Kim, Young-Hoon (National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Cha, Hye Jin (National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Han, Kyoung Moon (National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Shin, Jisoon (National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Oh, Hokyung (National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Jung, Kikyung (National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Ahn, Chiyoung (National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Park, Hye-Kyung (National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Kim, Hyung Soo (National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) |
1 | McKallip, R. J., Lombard, C., Fisher, M., Martin, B. R., Ryu, S., Grant, S., Nagarkatti, P. S. and Nagarkatti, M. (2002a) Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100, 627-634. DOI |
2 | McKallip, R. J., Lombard, C., Martin, B. R., Nagarkatti, M. and Nagarkatti, P. S. (2002b) -tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J. Pharmacol. Exp. Ther. 302, 451-465. DOI |
3 | Mocellin, S., Provenzano, M., Rossi, C. R., Pilati, P., Nitti, D. and Lise, M. (2003) Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment. J. Immunol. Methods 280, 1-11. DOI |
4 | Pascual, F. B., McGinley, E. L., Zanardi, L. R., Cortese, M. M. and Murphy, T. V. (2003) Tetanus surveillance--United States, 1998--2000. MMWR Surveill. Summ. 52, 1-8. |
5 | Rieder, S. A., Chauhan, A., Singh, U., Nagarkatti, M. and Nagarkatti, P. (2010) Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 215, 598-605. DOI |
6 | Robinson, R. H., Meissler, J. J., Breslow-Deckman, J. M., Gaughan, J., Adler, M. W. and Eisenstein, T. K. (2013) Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction. J. Neuroimmune Pharmacol. 8, 1239-1250. DOI |
7 | Robinson, R. H., Meissler, J. J., Fan, X., Yu, D., Adler, M. W. and Eisenstein, T. K. (2015) A CB2-selective cannabinoid suppresses T-cell activities and increases tregs and IL-10. J. Neuroimmune Pharmacol. 10, 318-332. DOI |
8 | Seely, K. A., Prather, P. L., James, L. P. and Moran, J. H. (2011) Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol. Interv. 11, 36-51. DOI |
9 | Starlets, D., Gore, Y., Binsky, I., Haran, M., Harpaz, N., Shvidel, L., Becker-Herman, S., Berrebi, A. and Shachar, I. (2006) Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 107, 4807-4816. DOI |
10 | Berdyshev, E. V. (2000) Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids 108, 169-190. DOI |
11 | Tanaka, Y., Koido, S., Xia, J., Ohana, M., Liu, C., Cote, G. M., Sawyer, D. B., Calderwood, S. and Gong, J. (2004) Development of antigen-specific CD8+ CTL in MHC class I-deficient mice through CD4 to CD8 conversion. J. Immunol. 172, 7848-7858. DOI |
12 | Vremec, D., Pooley, J., Hochrein, H., Wu, L. and Shortman, K. (2000) CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J. Immunol. 164, 2978-2986. DOI |
13 | Yamamoto, M., Wada, N., Kitabatake, Y., Watanabe, D., Anzai, M., Yokoyama, M., Teranishi, Y. and Nakanishi, S. (2003) Reversible suppression of glutamatergic neurotransmission of cerebellar granule cells in vivo by genetically manipulated expression of tetanus neurotoxin light chain. J. Neurosci. 23, 6759-6767. DOI |
14 | Yao, B. and Mackie, K. (2009) Endocannabinoid receptor pharmacology. Curr. Top. Behav. Neurosci. 1, 37-63. |
15 | Yeh, F. L., Dong, M., Yao, J., Tepp, W. H., Lin, G., Johnson, E. A. and Chapman, E. R. (2010) SV2 mediates entry of tetanus neurotoxin into central neurons. PLoS Pathog. 6, e1001207. DOI |
16 | Fattore, L. and Fratta, W. (2011) Beyond THC: The new generation of cannabinoid designer drugs. Front. Behav. Neurosci. 5, 60. |
17 | Blum, F. C., Chen, C., Kroken, A. R. and Barbieri, J. T. (2012) Tetanus toxin and botulinum toxin a utilize unique mechanisms to enter neurons of the central nervous system. Infect. Immun. 80, 1662-1669. DOI |
18 | Brazin, K. N., Mallis, R. J., Li, C., Keskin, D. B., Arthanari, H., Gao, Y., Wu, S. L., Karger, B. L., Wagner, G. and Reinherz, E. L. (2014) Constitutively oxidized CXXC motifs within the CD3 heterodimeric ectodomains of the T cell receptor complex enforce the conformation of juxtaposed segments. J. Biol. Chem. 289, 18880-18892. DOI |
19 | Cutando, L., Busquets-Garcia, A., Puighermanal, E., Gomis-Gonzalez, M., Delgado-Garcia, J. M., Gruart, A., Maldonado, R. and Ozaita, A. (2013) Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure. J. Clin. Invest. 123, 2816-2831. DOI |
20 | Friedman, H., Newton, C. and Klein, T. W. (2003) Microbial infections, immunomodulation, and drugs of abuse. Clin. Microbiol. Rev. 16, 209-219. DOI |
21 | Gagnon, E., Schubert, D. A., Gordo, S., Chu, H. H. and Wucherpfennig, K. W. (2012) Local changes in lipid environment of TCR microclusters regulate membrane binding by the CD3epsilon cytoplasmic domain. J. Exp. Med. 209, 2423-2439. DOI |
22 | Hermanns-Clausen, M., Kneisel, S., Szabo, B. and Auwarter, V. (2013) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108, 534-544. DOI |
23 | Hoffman, A. F., Laaris, N., Kawamura, M., Masino, S. A. and Lupica, C. R. (2010) Control of cannabinoid CB1 receptor function on glutamate axon terminals by endogenous adenosine acting at A1 receptors. J. Neurosci. 30, 545-555. DOI |
24 | Kim, J. C., Cook, M. N., Carey, M. R., Shen, C., Regehr, W. G. and Dymecki, S. M. (2009) Linking genetically defined neurons to behavior through a broadly applicable silencing allele. Neuron 63, 305-315. DOI |
25 | Hohmann, N., Mikus, G. and Czock, D. (2014) Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals. Dtsch. Arztebl. Int. 111, 139-147. |
26 | Huffman, J. W., Szklennik, P. V., Almond, A., Bushell, K., Selley, D. E., He, H., Cassidy, M. P., Wiley, J. L. and Martin, B. R. (2005a) 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg. Med. Chem. Lett. 15, 4110-4113. DOI |
27 | Huffman, J. W., Zengin, G., Wu, M. J., Lu, J., Hynd, G., Bushell, K., Thompson, A. L., Bushell, S., Tartal, C., Hurst, D. P., Reggio, P. H., Selley, D. E., Cassidy, M. P., Wiley, J. L. and Martin, B. R. (2005b) Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists. Bioorg. Med. Chem. 13, 89-112. DOI |
28 | Julio-Pieper, M., Flor, P. J., Dinan, T. G. and Cryan, J. F. (2011) Exciting times beyond the brain: metabotropic glutamate receptors in peripheral and non-neural tissues. Pharmacol. Rev. 63, 35-58. DOI |
29 | Kerblat, I., Tongiani-Dahshan, S., Aude-Garcia, C., Villiers, M., Drouet, C. and Marche, P. N. (2000) Tetanus toxin L chain is processed by major histocompatibility complex class I and class II pathways and recognized by CD8+ or CD4+ T lymphocytes. Immunology 100, 178-184. DOI |
30 | Kim, K. H., Ha, J. H., Chung, S. H., Kim, C. T., Kim, S. K., Hyun, B. H., Sawada, K., Fukui, Y., Park, I. K., Lee, G. J., Kim, B. K., Lee, N. S. and Jeong, Y. G. (2003) Glutamate and GABA concentrations in the cerebellum of novel ataxic mutant Pogo mice. J. Vet. Sci. 4, 209-212. |